Onsdag 28 Oktober | 18:11:32 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

Initiator Pharma Q1 report - Countdown to readouts

2023-05-05 11:45:00

Redeye provides a research update following the Q1 report published by Initiator Pharma earlier today. Overall, the report did not contain any significant surprises and was in line with our expectations. Accordingly, we reiterate our fair value range with a base case valuation of SEK13.5 as we look forward to the readouts from the company's three ongoing clinical trials expected later this year.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/